Navigation Links
Takeda Responds to Verdict in Diabetes Drug Case
Date:4/26/2013

DEERFIELD, Ill., April 26, 2013 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. announced today that in the case of Jack Cooper et al. v. Takeda Pharmaceuticals America, Inc., et al., No. CGC-12-518535 the jury found in favor of the plaintiffs and awarded a total of $6.5 million in damages. Takeda has filed motions asking the judge to rule in favor of the company as a matter of law and is considering its options, including a possible appeal if the motions are denied. The trial began on February 19 in Los Angeles before Judge Kenneth R. Freeman .

"Takeda respectfully disagrees with the jury's verdict," said Kenneth D. Greisman , senior vice president, general counsel and secretary, Takeda Pharmaceuticals U.S.A., Inc. "Takeda empathizes with patients like Mr. Cooper, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer.  We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS. We promptly disclosed ACTOS safety data to the U.S. Food & Drug Administration and other regulatory authorities and provided updated product information to health care professionals and patients."

The company is confident in the therapeutic benefits of ACTOS (pioglitazone HCl) and its importance as a treatment for type 2 diabetes.

"Patient safety is a critical priority for Takeda," said Greisman. "We plan to vigorously defend the company against future lawsuits."

Indication for ACTOS
ACTOS (pioglitazone) is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is not for the treatment of type 1 "juvenile" diabetes or diabetic ketoacidosis (increased ketones in blood or urine).

Important Safety Informati
'/>"/>

SOURCE Takeda Pharmaceuticals U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Launches New Subsidiary in Ecuador
2. Takeda lanza nueva subsidiaria en Ecuador
3. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
4. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
5. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
6. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
7. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
8. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
9. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
10. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
11. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014  Depomed, Inc. (NASDAQ: DEPO ) ... year 2014 financial results after the market closes on Wednesday, ... call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss ... by dialing 877-317-6789 ( United States ) ... available via a live webcast on the investor relations ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Full Service ... as the new Vice President of Business Development. Peter ... years in a number of different business development positions ... These positions were primarily related to business development/sales management ... past 30 years makes him a key and strategic ...
(Date:7/25/2014)... and Tobago , July 25, 2014 /PRNewswire/ ... Trinidad & Tobago Ministry of Health approved the ... that significantly increases the cure rate from Hepatitis ... with the genotype 1 virus. Telaprevir is available ... trade brand INCIVO®. Photo - ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... VRUS ) today announced that it will webcast ... of the Liver (EASL) on Saturday, April 2, 2011 starting ... progress on the programs that are the subject of presentations ... simultaneous webcast of this event via the internet, log on ...
... 25, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... confirmed that it has received a favorable decision from ... related to its ongoing patent challenge in connection with ... to market a generic version of Teva Women,s Health, ...
Cached Medicine Technology:Pharmasset to Webcast an Investor Event From the EASL Meeting 2Pharmasset to Webcast an Investor Event From the EASL Meeting 3Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge 2
(Date:7/25/2014)... The Little Gym of Houston will ... July 27 at Discovery Green in downtown Houston. The ... Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire ... “We’re thrilled to be attending and performing at the ... owns the Sugarland-Missouri City location. “We believe in the ...
(Date:7/25/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Ibuprofen and Oxcarbazepine Tablets . ... of Ibuprofen and one lot of Oxcarbazepine Tablets, by American ... packaging. Oxcarbazepine is used for the treatment of certain types ... reason for the recall is that Lot #142588, Expiration Date, ...
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
(Date:7/25/2014)... July 25, 2014 On July ... Nuanced Media client and the nation’s number one ... employee handbooks, announced their partnership with TransAct Merchant ... a registered ISO/MSP of Chase Paymentech Solutions, LLC, ... processing industry. Companies that are members of TransAct’s ...
(Date:7/25/2014)... Hastings and Hastings, a ... with regard to personal injury claims, announces free initial ... of legal services for those that have been injured ... or corporation. Free initial consultation services gives clients’ greater ... potential personal injury claim . It also offers ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... N.Y., March 23 You went on a diet. Great. ... keeping the weight off? What are your chances of avoiding ... Chronic Disease recommends that you turn to your doctor and ... measures the concentration of your IgG antibodies against two prevalent ...
... Study Adds to Growing Evidence of B. Infantis 35624 ... A review by researchers at Northwestern University ... , MI) of the utility of probiotics in the ... Bifidobacterium infantis 35624 was the only probiotic strain ...
... Physician-Owned Hospitals, According to New Reports from ... leading provider of managed care market intelligence, ... have traditionally enabled doctors practicing in the ... these regulations may actually yield increasing challenges ...
... for Distinguished Service in the Field of ChemistryEMERYVILLE, ... Alternext: NBY) today announced that world-renowned scientist M. ... Scientific Advisory Board will be the recipient of ... by the American Chemical Society (ACS). Dr. ...
... is One of Three FDA Approvals Spanning Lilly ... and Drug Administration (FDA) has approved a new ... Eli Lilly and Company (NYSE: LLY ... drug approved by the FDA for the acute ...
... PARK, Kan., March 23 According to the National ... recession since December 2007 and nearly half of U.S. ... iconic Oprah Winfrey replaced her annual ,Favorite Things, holiday ... "Thriftiest Holiday Ever!"However, the $200 billion health & wellness ...
Cached Medicine News:Health News:How to Keep the Weight Off? By Taking Gene-Eden, a New Dietary Supplement Based on Dr. Hanan Polansky's Discovery of the Cause of Many Diseases 2Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 2Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 3Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 4Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 5Health News:In Texas, Favorable Regulations for Physicians May Backfire in Light of Market Downturn 2Health News:NovaBay Pharmaceuticals' Scientific Advisor Receives American Chemical Society's Highest Award 2Health News:NovaBay Pharmaceuticals' Scientific Advisor Receives American Chemical Society's Highest Award 3Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 2Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 3Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 4Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 5Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 6Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 7Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 8Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 9Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 10Health News:Consumers Redefine Value in the Recession: Sauna Sales Prove Preventive Health Is an Essential Investment 2
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: